Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

829
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
829
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.9K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.9K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

831
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
831
Pulmonary Ventilation: Inhalation01:24

Pulmonary Ventilation: Inhalation

8.4K
Pulmonary ventilation is a vital process that ensures the exchange of oxygen and carbon dioxide in the lungs. It refers to the movement of air into and out of the lungs, enabling the body to obtain oxygen and remove waste carbon dioxide. In this article, we will explore the intricacies of pulmonary ventilation, including its underlying principles, mechanisms, and the interplay of pressures within the respiratory system.
Boyle's law becomes particularly pertinent when examining respiratory...
8.4K
Classical Conditioning in Daily Life01:17

Classical Conditioning in Daily Life

2.3K
Classical conditioning, a fundamental principle of associative learning, explains various phenomena observed in daily life, such as fear development, the placebo effect, taste aversion, and drug habituation. These applications demonstrate the profound impact of associative learning on human behavior and physiological responses.
John B. Watson and Rosalie Rayner famously demonstrated the development of fear through classical conditioning in their experiment with Little Albert. They paired the...
2.3K
Scalar and Vector Triple Products01:06

Scalar and Vector Triple Products

4.5K
Two vectors can be multiplied using a scalar product or a vector product. The resultant of a scalar product is scalar, while with vector products, the resultant is a vector. These rules of the scalar or vector product between two vectors can be applied to multiple vectors to obtain meaningful combinations. The scalar triple product is the dot product of a vector with the cross product of two vectors.
The scalar triple product is the dot product of a vector with the cross product of two vectors....
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to Ariel and Suissa and to Calzetta and Rogliani.

American journal of respiratory and critical care medicine·2024
Same author

Type 2 inflammation in COPD: is it just asthma?

Breathe (Sheffield, England)·2024
Same author

Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS).

Respiratory medicine·2024
Same author

ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD.

The European respiratory journal·2024
Same author

Call to Action: How Can We Promote the Development of New Pharmacologic Treatments in Chronic Obstructive Pulmonary Disease?

American journal of respiratory and critical care medicine·2024
Same author

Radiomultiomics: quantitative CT clusters of severe asthma associated with multiomics.

The European respiratory journal·2024

Related Experiment Video

Updated: Feb 11, 2026

Motor Dual-Tasks for Gait Analysis and Evaluation in Post-Stroke Patients
05:23

Motor Dual-Tasks for Gait Analysis and Evaluation in Post-Stroke Patients

Published on: March 11, 2021

2.9K

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

David A Lipson1, Frank Barnhart1, Noushin Brealey1

  • 1From GlaxoSmithKline, Collegeville (D.A. Lipson, J.B., S.J.P.), and the Perelman School of Medicine, University of Pennsylvania (D.A. Lipson), and Lewis Katz School of Medicine at Temple University (G.J.C.), Philadelphia - all in Pennsylvania; GlaxoSmithKline, Research Triangle Park, NC (F.B., C.E.J.); GlaxoSmithKline, Stockley Park West, Uxbridge (N.B., N.C.D., S.K., M.T.), the Department of Respiratory Medicine, Royal Devon and Exeter Hospital, Exeter (D.M.G.H.), UCL Respiratory, University College London, London (D.A. Lomas), and the Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, Manchester (D.S.) - all in the United Kingdom; the Division of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham (M.T.D.); the Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor (M.K.H.); the Department of Public Health, University of Copenhagen, Copenhagen (P.L.), and the Medical Department, Pulmonary Section, Herlev-Gentofte Hospital, Herlev (P.L.) - both in Denmark; New York-Presbyterian Hospital/Weill Cornell Medical Center, New York (F.J.M.); and the Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore (R.A.W.).

The New England Journal of Medicine
|April 19, 2018
PubMed
Summary

Triple therapy for COPD significantly reduced exacerbations compared to dual therapies. However, it increased the risk of pneumonia, indicating a trade-off in treatment benefits.

More Related Videos

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.8K
Brain-Computer Interface-controlled Upper Limb Robotic System for Enhancing Daily Activities in Stroke Patients
06:11

Brain-Computer Interface-controlled Upper Limb Robotic System for Enhancing Daily Activities in Stroke Patients

Published on: April 18, 2025

1.7K

Related Experiment Videos

Last Updated: Feb 11, 2026

Motor Dual-Tasks for Gait Analysis and Evaluation in Post-Stroke Patients
05:23

Motor Dual-Tasks for Gait Analysis and Evaluation in Post-Stroke Patients

Published on: March 11, 2021

2.9K
Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
07:42

Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients

Published on: December 16, 2022

3.8K
Brain-Computer Interface-controlled Upper Limb Robotic System for Enhancing Daily Activities in Stroke Patients
06:11

Brain-Computer Interface-controlled Upper Limb Robotic System for Enhancing Daily Activities in Stroke Patients

Published on: April 18, 2025

1.7K

Area of Science:

  • Pulmonology
  • Clinical Trials
  • Pharmacology

Background:

  • Uncertainty exists regarding the benefits of triple therapy (inhaled glucocorticoid, LAMA, LABA) versus dual therapy for COPD.
  • Dual therapy options include inhaled glucocorticoid-LABA or LAMA-LABA combinations.

Purpose of the Study:

  • To compare the efficacy and safety of once-daily triple therapy with fluticasone furoate, umeclidinium, and vilanterol against dual therapy regimens in COPD patients.
  • To evaluate the annual rate of moderate or severe COPD exacerbations as the primary outcome.

Main Methods:

  • A randomized trial involving 10,355 COPD patients over 52 weeks.
  • Comparison of triple therapy (fluticasone furoate, umeclidinium, vilanterol) with two dual therapy groups: fluticasone furoate-vilanterol and umeclidinium-vilanterol.
  • All regimens administered via a single Ellipta inhaler.

Main Results:

  • Triple therapy showed a 15% reduction in moderate/severe exacerbations versus fluticasone furoate-vilanterol (P<0.001) and a 25% reduction versus umeclidinium-vilanterol (P<0.001).
  • Triple therapy reduced severe exacerbations leading to hospitalization by 34% compared to umeclidinium-vilanterol (P<0.001).
  • Pneumonia incidence was higher in inhaled-glucocorticoid groups; triple therapy significantly increased pneumonia risk versus umeclidinium-vilanterol (HR, 1.53; P<0.001).

Conclusions:

  • Triple therapy with fluticasone furoate, umeclidinium, and vilanterol is more effective in reducing moderate/severe COPD exacerbations than dual therapies.
  • Triple therapy also lowers hospitalization rates due to COPD exacerbations compared to umeclidinium-vilanterol.
  • Increased pneumonia risk with triple therapy necessitates careful consideration of the benefit-risk profile.